Treatment with the investigational single-agent belantamab mafodotin resulted in a 31% overall response rate with the 2.5 mg/kg regimen in patients with heavily pre-treated multiple myeloma.
On Aug. 26, FDA approved the RAS inhibitor, daraxonrasib, sponsored by Revolution Medicines Inc. and also known as Rasonque, for patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.
